Friday, December 01, 2017 11:07:50 AM
The Placebo Effect
It is well known and understood.
https://www.medicinenet.com/script/main/art.asp?articlekey=31481
It occurs when an inactive substance such as sugar, distilled water, or saline solution is medically administered under the guise that it’s a real drug to treat a real disease, with supposed real benefits; whereupon the unknowing patient, because of expectation thinks its helpful.
Thereby (in some cases) the expectation causes the patient to thoroughly believe and act as if the “drug” made the condition better, with perceived reduction in symptom severity or duration.
All of this is psychologically-induced by belief or expectation, not by the “drug,” an utterly inactive substance. The actual nature of the “relief” is not an issue, whether or not actual pain perception, for example, was actually suppressed by the “drug.” The only consideration is patient's perception.
Concerning Anavex 2-73 and the patients that drug targets, the placebo effect has important considerations.
In the case of Alzheimer’s dementia and cognition decline, can there possibly be an authentic placebo effect, where mid- to mild-level Alzheimer’s patients a) cognitively understand what Anavex 2-73 is “supposed” to do for them, creating a placebo expectation, and b) are such patients capable of self-restoration of cognition by any sort of self-devised, internal psychological trickery?
Inasmuch as the dementia problems of Alzheimer’s are caused by cytological and histological dysfunctions in neurons and nerves directly involving several actual toxic chemicals and reaction cascades, there are simply no cases of any sort of placebo effects in Alzheimer's disease. Chemically difficult (well, impossible).
Very similar with Rett syndrome patients. First, these are neurologically compromised little girls. Their ability, at least in some cases, to understand that some new pill they will be taking should suppress their epileptic fits and motor neuron hyperactivities and poor muscle control is minimal, at best. Hard to conceive how they could formulate the expectations of improved health required for the placebo effect to actually happen.
It is well known and understood.
https://www.medicinenet.com/script/main/art.asp?articlekey=31481
It occurs when an inactive substance such as sugar, distilled water, or saline solution is medically administered under the guise that it’s a real drug to treat a real disease, with supposed real benefits; whereupon the unknowing patient, because of expectation thinks its helpful.
Thereby (in some cases) the expectation causes the patient to thoroughly believe and act as if the “drug” made the condition better, with perceived reduction in symptom severity or duration.
All of this is psychologically-induced by belief or expectation, not by the “drug,” an utterly inactive substance. The actual nature of the “relief” is not an issue, whether or not actual pain perception, for example, was actually suppressed by the “drug.” The only consideration is patient's perception.
Concerning Anavex 2-73 and the patients that drug targets, the placebo effect has important considerations.
In the case of Alzheimer’s dementia and cognition decline, can there possibly be an authentic placebo effect, where mid- to mild-level Alzheimer’s patients a) cognitively understand what Anavex 2-73 is “supposed” to do for them, creating a placebo expectation, and b) are such patients capable of self-restoration of cognition by any sort of self-devised, internal psychological trickery?
Inasmuch as the dementia problems of Alzheimer’s are caused by cytological and histological dysfunctions in neurons and nerves directly involving several actual toxic chemicals and reaction cascades, there are simply no cases of any sort of placebo effects in Alzheimer's disease. Chemically difficult (well, impossible).
Very similar with Rett syndrome patients. First, these are neurologically compromised little girls. Their ability, at least in some cases, to understand that some new pill they will be taking should suppress their epileptic fits and motor neuron hyperactivities and poor muscle control is minimal, at best. Hard to conceive how they could formulate the expectations of improved health required for the placebo effect to actually happen.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
